Misplaced Pages

#555444

30-419: TRH has been used clinically for the treatment of spinocerebellar degeneration and disturbance of consciousness in humans. Its pharmaceutical form is called protirelin ( INN ) ( / p r oʊ ˈ t aɪ r ɪ l ɪ n / ). TRH is synthesized within parvocellular neurons of the paraventricular nucleus of the hypothalamus. It is translated as a 242-amino acid precursor polypeptide that contains 6 copies of

60-437: A polyglutamine trinucleotide repeat CAG expansion, a longer expansion may lead to an earlier onset and a more radical progression of clinical symptoms. Typically, a person with this disease will eventually be unable to perform daily tasks (ADLs). However, rehabilitation therapists can help patients to maximize their ability of self-care and delay deterioration to certain extent. Researchers are exploring multiple avenues for

90-611: A cure including RNA interference (RNAi) technology, the use of stem cells, and several other avenues. On January 18, 2017, BioBlast Pharma announced completion of Phase 2a clinical trials of their medication, trehalose , in the treatment of SCA3. BioBlast has received FDA Fast Track status and orphan drug status for their treatment. The information provided by BioBlast in their research indicates that they hope this treatment may prove efficacious in other SCA treatments that have similar pathology related to PolyA and PolyQ diseases. In addition, Dr. Beverly Davidson has been working on

120-415: A disease affects whether it is considered acute or chronic . By definition, virtually all slowly progressive diseases are also chronic diseases . Biologically, many of these are also referred to as degenerative diseases due to the cellular changes. Not all chronic diseases are progressive: a chronic, non-progressive disease may be referred to as a static condition. Progressive disease can also be

150-455: A gain of two SARA points (Scale for the Assessment and Rating of Ataxia) from physical therapy. In general, physical therapy emphasises postural balance and gait training for ataxia patients. General conditioning such as range-of-motion exercises and muscle strengthening would also be included in therapeutic exercise programmes. Research showed that spinocerebellar ataxia 2 (SCA2) patients with

180-508: A methodology using RNAi technology to find a potential cure for over 2 decades. Her research began in the mid-1990s and progressed to work with mouse models about a decade later and most recently has moved to a study with non-human primates. The results from her most recent research "are supportive of clinical application of this gene therapy". Finally, another gene transfer technology discovered in 2011 has also been shown by Boudreau et al. to hold great promise and offers yet another avenue to

210-795: A mild stage of the disease gained significant improvement in static balance and neurological indices after six months of a physical therapy exercise training program. Occupational therapists may assist patients with incoordination or ataxia issues through the use of adaptive devices. Such devices may include a cane, crutches, walker, or wheelchair for those with impaired gait . Other devices are available to assist with writing, feeding, and self care if hand and arm coordination are impaired. A randomised clinical trial revealed that an intensive rehabilitation program with physical and occupational therapies for patients with degenerative cerebellar diseases can significantly improve functional gains in ataxia, gait, and activities of daily living. Some level of improvement

240-488: A physical exam, family history, MRI scanning of the brain and spine, and spinal tap. Many SCAs below fall under the category of polyglutamine diseases, which are caused when a disease-associated protein (i.e., ataxin-1, ataxin-3, etc.) contains a large number of repeats of glutamine residues, termed a polyQ sequence or a "CAG trinucleotide repeat " disease for either the one-letter designation or codon for glutamine respectively. The threshold for symptoms in most forms of SCA

270-471: A potential future cure. N-Acetyl-Leucine is an orally administered, modified amino acid that is being developed as a novel treatment for multiple rare and common neurological disorders by IntraBio Inc (Oxford, United Kingdom). N-Acetyl-Leucine has been granted multiple orphan drug designations from the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) for

300-464: A series of enzymes collectively known as peptidylglycine-alpha-amidating monooxygenase. Concurrently with these processing steps, the N-terminal Gln ( glutamine ) is converted into pyroglutamate (a cyclic residue). These multiple steps produce 6 copies of the mature TRH molecule per precursor molecule for human TRH (5 for mouse TRH). TRH synthesizing neurons of the paraventricular nucleus project to

330-477: Is a progressive , degenerative , genetic disease with multiple types, each of which could be considered a neurological condition in its own right. An estimated 150,000 people in the United States have a diagnosis of spinocerebellar ataxia at any given time . SCA is hereditary, progressive, degenerative, and often fatal. There is no known effective treatment or cure. SCA can affect anyone of any age. The disease

SECTION 10

#1733106391556

360-558: Is a list of some of the many types of Spinocerebellar ataxia . Others include SCA18 , SCA20 , SCA21 , SCA23 , SCA26 , SCA28 , and SCA29 . Four X-linked types have been described ( 302500 , 302600 , 301790 , 301840 ), but only the first of these has so far been tied to a gene ( SCAX1 ). There is no cure for spinocerebellar ataxia, which is currently considered to be a progressive and irreversible disease, although not all types cause equally severe disability. In general, treatments are directed towards alleviating symptoms, not

390-505: Is a tripeptide, with an amino acid sequence of pyroglutamyl-histidyl-proline amide. The structure of TRH was first determined, and the hormone synthesized, by Roger Guillemin and Andrew V. Schally in 1969. Both parties insisted their labs determined the sequence first: Schally first suggested the possibility in 1966, but abandoned it after Guillemin proposed TRH was not actually a peptide. Guillemin's chemist began concurring with these results in 1969, as NIH threatened to cut off funding for

420-413: Is administered intrathecally, or administration into the spine, and the effects are short-lived. Some researchers are testing a prodrug approach to administer TRH orally and have TRH reach the brain without being degraded in the stomach or blood. TRH has been shown in mice to be an anti-aging agent with a broad spectrum of activities that, because of their actions, suggest that TRH has a fundamental role in

450-466: Is around 35, though for SCA3 it extends beyond 50. Most polyglutamine diseases are dominant due to the interactions of resulting polyQ tail. The first ataxia gene was identified in 1993 and called "Spinocerebellar ataxia type 1" (SCA1); later genes were called SCA2, SCA3, etc. Usually, the "type" number of "SCA" refers to the order in which the gene was found. At this time, there are at least 49 different gene mutations that have been found. The following

480-541: Is caused by either a recessive or dominant gene. In many cases people are not aware that they carry a relevant gene until they have children who begin to show signs of having the disorder. Currently, research is being conducted at Universities, such as the University of Minnesota, to elucidate many of the unknown characteristics of the disease. Spinocerebellar ataxia (SCA) is one of a group of genetic disorders characterized by slowly progressive incoordination of gait and

510-559: Is often associated with poor coordination of hands, speech, and eye movements. A review of different clinical features among SCA subtypes was recently published describing the frequency of non-cerebellar features, like parkinsonism, chorea, pyramidalism, cognitive impairment, peripheral neuropathy, seizures, among others. As with other forms of ataxia, SCA frequently results in atrophy of the cerebellum , loss of fine coordination of muscle movements leading to unsteady and clumsy motion, and other symptoms. Ocular deficits can be quantified using

540-505: Is the worsening, growth, or spread of the disease. This may happen until death , serious debility , or organ failure occurs. Some progressive diseases can be halted and reversed by treatment (surgical, dietary, or lifestyle interventions). Many can be slowed by medical therapy . Some cannot be altered by current treatments. Though the time distinctions are imprecise, diseases can be rapidly progressive (typically days to weeks) or slowly progressive (months to years). The time course of

570-712: The SODA scale. The symptoms of an ataxia vary with the specific type and with the individual patient. Many subtypes of spinocerebellar ataxia result in cases where an individual retains full mental capacity but progressively loses physical control, but nearly half of the identified subtypes result in cognitive dysfunction, dementia, and mental retardation. The hereditary ataxias are categorized by mode of inheritance and causative gene or chromosomal locus. The hereditary ataxias can be inherited in an autosomal dominant , autosomal recessive , or X-linked manner . A few SCAs remain unspecified and can not be precisely diagnosed, but in

600-403: The disease itself. Many patients with hereditary or idiopathic forms of ataxia have other symptoms in addition to ataxia. Medications or other therapies might be appropriate for some of these symptoms, which could include tremor, stiffness, depression , spasticity , and sleep disorders , among others. Both onset of initial symptoms and duration of disease are variable. If the disease is caused by

630-401: The last decade genetic testing has allowed precise identification of dozens of different SCAs and more tests are being added each year. In 2008, a genetic ataxia blood test developed to test for 12 types of SCA, Friedreich's ataxia , and several others. However, since not every SCA has been genetically identified some SCAs are still diagnosed by neurological examination, which may include

SECTION 20

#1733106391556

660-447: The medial portion of the external layer of the median eminence. Following secretion at the median eminence , TRH travels to the anterior pituitary via the hypophyseal portal system where it binds to the TRH receptor stimulating the release of thyroid-stimulating hormone from thyrotropes and prolactin from lactotropes . The half-life of TRH in the blood is approximately 6 minutes. TRH

690-499: The project, leading both parties to return to work on synthesis. Schally and Guillemin shared the 1977 Nobel Prize in Medicine "for their discoveries concerning the peptide hormone production of the brain." News accounts of their work often focused on their "fierce competition" and use of a very large amount of sheep and pig brains to locate the hormone. TRH is used clinically by intravenous injection (brand name Relefact TRH) to test

720-410: The regulation of metabolic and hormonal functions. Side effects after intravenous TRH administration are minimal. Nausea, flushing, urinary urgency, and mild rise in blood pressure have been reported. After intrathecal administration, shaking, sweating, shivering, restlessness, and mild rise in blood pressure were observed. Spinocerebellar degeneration Spinocerebellar ataxia ( SCA )

750-440: The response of the anterior pituitary gland ; this procedure is known as a TRH test . This is done as diagnostic test of thyroid disorders such as secondary hypothyroidism and in acromegaly . TRH has anti-depressant and anti-suicidal properties, and in 2012 the U.S. Army awarded a research grant to develop a TRH nasal spray in order to prevent suicide amongst its ranks. The antidepressant properties of TRH are present when TRH

780-503: The sequence -Gln-His-Pro-Gly-, with both ends of the sequence flanked by Lys-Arg or Arg-Arg sequences. To produce the mature form, a series of enzymes are required. First, a protease cleaves to the C-terminal side of the flanking Lys-Arg or Arg-Arg. Second, a carboxypeptidase removes the Lys/Arg residues leaving Gly as the C-terminal residue. Then, this Gly is converted into an amide residue by

810-457: The treatment of Niemann-Pick disease type C and GM2 gangliosidosis ( Tay-Sachs and Sandhoff disease). Future opportunities to develop N-Acetyl-Leucine include Lewy body dementia , amyotrophic lateral sclerosis , restless leg syndrome , multiple sclerosis , and migraine . Physical therapists can assist patients in maintaining their level of independence through therapeutic exercise programmes. One recent research report demonstrated

840-433: The treatment of inherited cerebellar ataxias, including spinocerebellar ataxias. These studies further demonstrated that the treatment is well tolerated, with a good safety profile. A multinational clinical trial investigating N-Acetyl-L-Leucine for the treatment of a related inherited cerebellar ataxia, ataxia-telangiectasia , began in 2019. IntraBio is also conducting parallel clinical trials with N-Acetyl-L-Leucine for

870-465: The treatment of various genetic diseases, including spinocerebellar ataxias. N-Acetyl-Leucine has also been granted Orphan Drug Designations in the US and EU for the related inherited cerebellar ataxia ataxia-telangiectasia U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA). Published case series studies have demonstrated the effects of acute treatment with N-Acetyl-Leucine for

900-403: Was shown to be maintained 24 weeks post-treatment. Speech language pathologists may use both behavioral intervention strategies as well as augmentative and alternative communication devices to help patients with impaired speech. Creutzfeldt–Jakob disease Progressive disease Progressive disease or progressive illness is a disease or physical ailment whose course in most cases

#555444